DermTech, Inc., a molecular genomics company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company sells its products to pathology and oncology practitioners. DermTech, Inc. was incorporated in 1995 and is headquartered in La Jolla, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-450-4222
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees36
Next Earnings Date2/27/2020 (Estimated)
OptionableNot Optionable
DermTech (NASDAQ:DMTK) Frequently Asked Questions
What is DermTech's stock symbol?
DermTech trades on the NASDAQ under the ticker symbol "DMTK."
When is DermTech's next earnings date?
What price target have analysts set for DMTK?
1 brokers have issued 1 year price targets for DermTech's stock. Their forecasts range from $15.00 to $15.00. On average, they expect DermTech's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 22.0% from the stock's current price. View Analyst Price Targets for DermTech.
What is the consensus analysts' recommendation for DermTech?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DermTech.
Has DermTech been receiving favorable news coverage?
News articles about DMTK stock have trended positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DermTech earned a news impact score of 2.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for DermTech.
Are investors shorting DermTech?
DermTech saw a drop in short interest in January. As of January 31st, there was short interest totalling 84,400 shares, a drop of 30.0% from the January 15th total of 120,600 shares. Based on an average trading volume of 59,800 shares, the short-interest ratio is currently 1.4 days. Approximately 1.6% of the company's shares are short sold. View DermTech's Current Options Chain.
Who are some of DermTech's key competitors?
Some companies that are related to DermTech include Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Personalis (PSNL), Centogene (CNTG), Anpac Bio-Medical Science (ANPC), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), Cancer Genetics (CGIX) and OpGen (OPGN).
What other stocks do shareholders of DermTech own?
Who are DermTech's key executives?
DermTech's management team includes the folowing people:
- Dr. John D. Dobak, Pres, CEO & Director (Age 53)
- Mr. Kevin Sun, CFO, Treasurer & Sec.
- Ms. Claudia Ibarra, Chief Operating Officer (Age 57)
- Dr. Zuxu Yao, Chief Scientific Officer (Age 57)
- Ms. Sarah Dennison, VP of Marketing
Who are DermTech's major shareholders?
DermTech's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Cowen AND Company LLC (1.17%) and Virtu Financial LLC (0.11%).
Which institutional investors are selling DermTech stock?
DMTK stock was sold by a variety of institutional investors in the last quarter, including Cowen AND Company LLC.
Which institutional investors are buying DermTech stock?
DMTK stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
How do I buy shares of DermTech?
Shares of DMTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is DermTech's stock price today?
One share of DMTK stock can currently be purchased for approximately $12.30.
How big of a company is DermTech?
What is DermTech's official website?
How can I contact DermTech?
DermTech's mailing address is 11099 N. TORREY PINES ROAD SUITE 100, LA JOLLA CA, 92037. The company can be reached via phone at 858-450-4222.
MarketBeat Community Rating for DermTech (NASDAQ DMTK)
MarketBeat's community ratings are surveys of what our community members think about DermTech and other stocks. Vote "Outperform" if you believe DMTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
